Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — ESMO 2023 poster webinar
29 slides from Lytix Biopharma ASA's conference presentation, Oct 23, 2023
Slide 1: Presentation of ATLAS-IT-05 ESMO poster
Presentation of ATLAS-IT-05 ESMO poster Interim data and ATLAS-IT-05 Update Webinar October 23rd 2023
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Lytix Biopharma in Brief
LYTIX BIOPHARMA IN BRIEF Company overview Key Highlights A listed, Norwegian, clinical-stage, immuno- Positioned in the fastest growing segment in pharma, oncology company 1 with revenue potential estimated to USD 120 bn Broad technology platform derived from world First in class molecules with pote
Slide 4: ATLAS-IT-05 Data Snapshot - ESMO 2023 Poster Presentation
ATLAS-IT-05 DATA SNAPSHOT - ESMO 2023 POSTER PRESENTATION 4
Slide 5: LTX-315 - Unique Mode of Action Results in Effective Release of Immunostimulants
LTX-315 - UNIQUE MODE OF ACTION RESULTS IN EFFECTIVE RELEASE OF POTENT IMMUNOSTIMULANTS AND ANTIGENS 5
Slide 6: RECIST Version 1.1 - Definitions
RECIST VERSION 1.1 - DEFINITIONS Complete response: disappearance of all tumor lesions Partial response: ≥30% decrease of target lesion(s) Progressive disease: ≥20% increase of target lesion(s) or presence of new lesion(s) Stable disease: neither partial response nor progressive disease Objective Re
Slide 7: Study Objectives and Endpoints
STUDY OBJECTIVES AND ENDPOINTS Objectives Evaluate the efficacy and safety of intratumoral LTX-315 in combination with pembrolizumab in patients with Stage IIIB-IVm1b melanoma, who have progressed on or after prior treatment with a PD-1/PD-L1 inhibitor Primary Efficacy Endpoint Objective Response Ra
Slide 8: ATLAS-IT-05 Study Design
ATLAS-IT-05 STUDY DESIGN Open label, single-arm, Phase II study with 10 study sites in Europe and the US (NCT04796194) 8
Slide 9: Key Inclusion and Exclusion Criteria
KEY INCLUSION AND EXCLUSION CRITERIA Stage IIIB-IVm1b unresectable melanoma Confirmed disease progression on or after prior treatment with PD-1/PD-L1 inhibitor ≤3 prior lines of systemic treatment for metastatic disease At least 1 superficial tumor lesion accessible for injection ATLAS-IT-05 enrolle
Slide 10: Patient Disposition in First Data Snapshot
10 PATIENT DISPOSITION IN FIRST DATA SNAPSHOT Number of patients Patients included in Safety Analysis Set (SAS) 20 Patients included in Efficacy Analysis Set (EAS) 14 The cutoff date for this data snapshot was 13 September 2023 Median duration of follow-up was limited at the cutoff date - only 15 we
Slide 11: Patient Population with Very Advanced Melanoma Disease and Poor Prognostic Baseline Factors
PATIENT POPULATION WITH VERY ADVANCED MELANOMA DISEASE AND POOR PROGNOSTIC BASELINE FACTORS Majority of patients (60%) had Stage IV disease and relatively high tumor burden 40% of patients had received 2 or more prior anti-cancer treatments in an advanced, metastatic disease setting – including some
Slide 12: Best Overall Response - RECIST Version 1.1
BEST OVERALL RESPONSE - RECIST VERSION 1.1 Best overall response in EAS (n=14) n (%) Complete response 0 (0%) Partial Response* 1 (7%) Stable Disease 5 (36%) Progressive Disease 8 (57%) Objective Response Rate (ORR) = 7% (95% CI 1-30%) Disease Control Rate (DCR)= 43% (95% CI 20-70%) *Response was co
Slide 13: Change in RECIST Target Lesions
BOR PR CHANGE IN RECIST TARGET LESIONS SD PD On treatment 140% % Change in RECIST target lesions from baseline 120% 100% 80% PD 60% 40% 20% PR SD 0% -20% -40% PR -60% -80% -100% SCREENING D43 D106 D169 D232 Treatment Day 43% of patients included in this analysis are still on study treatment and stil
Slide 14: Response in Injected Lesions
RESPONSE IN INJECTED LESIONS ▪ 9 out of 21 (43%) evaluable injected lesions showed 100% complete regression by CT scan after start of treatment ▪ Any partial responses were not captured in this assessment by CT ▪ Updated and more mature data on responses in injected lesions will be presented in the
Slide 15: Response in Injected Lesions
RESPONSE IN INJECTED LESIONS ▪ Patient with multiple large tumor lesions on right forearm that were injected with LTX-315* ▪ Clear signs of necrosis and regression of injected tumor lesions on Day 43 *Patient was technically classified as PD due to emergence of a small lesion in the finger 15
Slide 16: LTX-315-Related Adverse Events
LTX-315-RELATED ADVERSE EVENTS Adverse event Mild Moderate Severe Death Patients - n (%) Injection site 10 (50%) 5 (25%) 0 0 15 (75%) pain Injection site 3 (15%) 1 (5%) 0 0 4 (20%) erythema Injection site 3 (15%) 0 0 0 3 (15%) swelling The most common (>10%) LTX-315-related adverse events were local
Slide 17: Case #1 – Melanoma Patient with Local and Systemic Response
CASE #1 – MELANOMA PATIENT WITH CLINICALLY RELEVANT LOCAL AND SYSTEMIC RESPONSE 75-year-old male with Stage IVm1a, nodular melanoma (BRAF positive) Multiple metastases in lymph nodes and gluteal muscle at baseline Prior treatment with nivolumab (adjuvant setting) and BRAF/Mek inhibitor (metastatic s
Slide 18: Non-Injected Lesion and Injected Lesions
NON-INJECTED LESION INJECTED LESIONS Target lesion size 28 mm 26 mm 3 mm 89% tumor shrinkage ▪ Complete regression of all injected lesions 18
Slide 19: Case #2 – Melanoma Patient with Systemic Response but PD Due to New Lesion
CASE #2 – MELANOMA PATIENT WITH CLINICALLY RELEVANT SYSTEMIC RESPONSE BUT PD DUE TO NEW LESION 77-year-old female patient with stage IVm1a melanoma Prior treatment with nivolumab in metastatic setting – disease progression while on treatment Treated with in total 30 intratumoral LTX-315 injections i
Slide 20: Case #2 – Change in Size of Non-Injected Lesions
CASE #2 – MELANOMA PATIENT WITH CLINICALLY RELEVANT SYSTEMIC RESPONSE BUT PD DUE TO NEW LESION Change in size of non-injected lesions 25 Two non-injected lesions (TL01 and TL02) reduced in 20 size (-36%) lesion size- longest diamter (mm) 15 One new lesion (TL03 - lymph 10 node) appeared at day 106 5
Slide 21: Case #3 – Acinic Cell Carcinoma Patient with Deep and Durable Response
CASE #3 – ACINIC CELL CARCINOMA PATIENT WITH DEEP AND DURABLE RESPONSE (NOT PRESENTED AT ESMO) 62-year-old female with stage IV acinic cell carcinoma was enrolled under a prior version of the study protocol Multiple metastases in bone, peritoneum, breast, adrenal gland and lung No prior treatment wi
Slide 22: Case #3 – Acinic Cell Carcinoma Target Lesion Response
CASE #3 – ACINIC CELL CARCINOMA PATIENT WITH DEEP AND DURABLE RESPONSE (NOT PRESENTED AT ESMO) TARGET LESION ▪ Complete regression of non-injected 100% % Change in RECIST target lesion from target lesion (100% shrinkage) 80% 60% 40% ▪ Very durable response (>1.5 years) 20% baseline 0% suggesting a l
Slide 23: Conclusions Based on First Data Snapshot
CONCLUSIONS BASED ON FIRST DATA SNAPSHOT The combination regimen demonstrates preliminary signs of tumor shrinkage and prolonged stabilization in heavily pre-treated patients with PD-1/PD-L1 inhibitor refractory metastatic melanoma. ‒ Enrolled patients had generally poor prognostic factors and some
Slide 24: ATLAS-IT-05 - Next Steps
ATLAS-IT-05 - NEXT STEPS 2023 2024 2025 H2 H1 H2 H1 H2 ATLAS-IT-05 Interim readout at Top line data first Top line data expansion LTX-315 in combination with ESMO (14 pts.) cohort (20 pts.) cohort (20 pts.) pembrolizumab in melanoma Top line data from first cohort - H1 2024 New amendment for initiat
Slide 25: Planned Neoadjuvant Study: LTX-315 in Earlier Stage Melanoma Patients
PLANNED NEOADJUVANT STUDY: -LTX-315 IN EARLIER STAGE MELANOMA PATIENTS Neoadjuvant LTX-315 added to standard of care immune checkpoint inhibitor (pembrolizumab) in resectable stage III/IV melanoma Principal investigator, dr. Henrik Jespersen, Head of melanoma oncology, Oslo University Hospital - Rad
Slide 26: Positive Early Results from Ongoing Phase II Study in Basal Cell Carcinoma
POSITIVE EARLY RESULTS FROM ONGOING PHASE II STUDY IN BASAL CELL CARCINOMA ‒ Of the six patients treated with LTX-315 at the highest dose, complete clearance was observed in four injected lesions, 95% and 30% clearance in two other injected lesions Phase II study expected to be completed mid 2024 26
Slide 27: Basal Cell Carcinoma Market
BASAL CELL CARCINOMA MARKET Current treatment(s) for BCC are invasive, painful, disfiguring, and may require destruction of healthy tissue • LTX-315 represent a non-surgical alternative for patients suffering from skin cancer The BCC market size is expected to increase from 6.7 billion USD in 2021 t
Slide 28: LTX-401: Optimized for Deep-Seated Solid Tumors
LTX-401: OPTIMIZED FOR DEEP-SEATED SOLID TUMORS Superior effects in several LTX-401 cured 50% of the animals with liver different pre-clinical cancer cancer models, including liver cancer Strong synergy with checkpoint inhibitors Favorable safety profile Phase I ready Fully owned Ideal for deep seat
Slide 29: Summary
SUMMARY The combination with LTX-315 and pembrolizumab demonstrates encouraging preliminary result in heavily pre-treated melanoma patient with one partial response and a disease control rate of 43% Top line data from all 20 patients in cohort 1 will be presented in Q1 2024. An amendment for the ini